Elite in Nonalcoholic Steatohepatitis (NASH)

Dr. Arun J. Sanyal

Gastroenterology
Mcv Associated Physicians
1200 E Marshall St, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
39 Years of Experience
Elite in Nonalcoholic Steatohepatitis (NASH)
Mcv Associated Physicians
1200 E Marshall St, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arun Sanyal is a Gastroenterologist in Richmond, Virginia. Dr. Sanyal has been practicing medicine for over 39 years and is rated as an Elite provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Endoscopy. Dr. Sanyal is currently accepting new patients.

His clinical research consists of co-authoring 672 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 116 articles and participated in 5 clinical trials in the study of Nonalcoholic Steatohepatitis (NASH).

Specialties
Gastroenterology
Licenses
Internal Medicine in VA
Hospital Affiliations
Medical College Of Virginia Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1200 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
Enrollment Status: Suspended
Publish Date: November 13, 2025
Intervention Type: Device
Study Phase: Not Applicable
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Vitamin E
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Enrollment Status: Completed
Publish Date: August 13, 2025
A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium
A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: Anakinra and Zinc, Prednisone
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
Enrollment Status: Completed
Publish Date: August 28, 2023
Intervention Type: Drug
Study Drugs: Vitamin C, Dextrose
Study Phase: Phase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Drug: MEDI0382
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug
Study Drug: AXA1665
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Enrollment Status: Completed
Publish Date: February 23, 2022
A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients
A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium
Enrollment Status: Completed
Publish Date: February 11, 2020
A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
Enrollment Status: Terminated
Publish Date: January 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis
A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
Enrollment Status: Completed
Publish Date: April 06, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 19 Less Clinical Trials

671 Total Publications

MASLD and MASH increase fracture risk in humans and mice by arresting new bone formation.
MASLD and MASH increase fracture risk in humans and mice by arresting new bone formation.
Journal: Research square
Published: December 08, 2025
Similar Doctors
Elite in Nonalcoholic Steatohepatitis (NASH)
Dr. Mohammad Siddiqui
Gastroenterology
Elite in Nonalcoholic Steatohepatitis (NASH)
Dr. Mohammad Siddiqui
Gastroenterology

Gastrointestinal Specialists Inc

7611 Forest Ave, Suite 320, 
Richmond, VA 
 (7.6 miles away)
804-285-2965
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mohammad Siddiqui is a Gastroenterologist in Richmond, Virginia. Dr. Siddiqui is rated as an Elite provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Failure, Liver Transplant, and Endoscopy.

Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Puneet Puri
Gastroenterology
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Puneet Puri
Gastroenterology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
 (0.1 miles away)
804-828-8508
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Puneet Puri is a Gastroenterologist in Richmond, Virginia. Dr. Puri is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Liver Failure, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, and Liver Transplant.

Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Velimir Luketic
Gastroenterology
Distinguished in Nonalcoholic Steatohepatitis (NASH)
Dr. Velimir Luketic
Gastroenterology

Mcv Associated Physicians

3470 Mayland Ct, 
Richmond, VA 
 (10.1 miles away)
804-527-4538
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Velimir Luketic is a Gastroenterologist in Richmond, Virginia. Dr. Luketic is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Primary Biliary Cholangitis, Cirrhosis, Liver Failure, Cholestasis, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanyal's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile